Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
暂无分享,去创建一个
G. Salles | M. Ghielmini | M. Dreyling | L. Vidal | R. Pettengell | O. Shpilberg | A. Gafter-Gvili | M. Witzens‐Harig | S. Hsu Schmitz
[1] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[2] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[3] K. Ardeshna,et al. An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy In Patients with Stage II, III, IV, Asymptomatic, Non-Bulky Follicular Lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis , 2010 .
[4] M. Ghielmini,et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Kimby,et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Marcus,et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] F. Cavalli,et al. Patterns of survival of follicular lymphomas at a single institution through three decades , 2010, Leukemia & lymphoma.
[8] N. Schmitz,et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. , 2010 .
[9] G. Salles,et al. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study , 2010, Leukemia & lymphoma.
[10] G. Salles,et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Marcus,et al. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma , 2009, British Journal of Cancer.
[12] M. Ghielmini,et al. First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Ghielmini,et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. , 2010, Journal of the National Cancer Institute.
[14] K. Herfarth,et al. Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy. , 2009 .
[15] A. Hagenbeek,et al. Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial , 2009, Journal of Nuclear Medicine.
[16] J. Hainsworth,et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. , 2009, Clinical lymphoma & myeloma.
[17] David Green,et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.
[18] F. Angrilli,et al. Anthracycline‐fludarabine‐containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma , 2009, Cancer.
[19] D. Spaner,et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma , 2009, Bone Marrow Transplantation.
[20] R. Gascoyne,et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Taniwaki,et al. Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma , 2009, Cancer science.
[22] G. Kronborg,et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. , 2009, The Journal of infectious diseases.
[23] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[24] L. Agodoa,et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. , 2008, Transplantation.
[25] S. Swerdlow,et al. Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma , 2008, Clinical Cancer Research.
[26] B. Coiffier,et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] K. Simpson,et al. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. , 2008, Clinical lymphoma & myeloma.
[28] H. Brenner,et al. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. , 2008, Archives of internal medicine.
[29] Yana Zhang,et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period , 2008, Leukemia & lymphoma.
[30] E. Kimby,et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group , 2008, Leukemia & lymphoma.
[31] E. Kimby,et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden , 2008, Acta oncologica.
[32] A. Ho,et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial , 2008, Annals of Hematology.
[33] R. Foà,et al. The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy. , 2007 .
[34] A. Berrebi,et al. Predictive Factors to Hypogammaglobulinemia and Non-Neutropenic Infection Complications after Rituximab/Chemotherapy Treatment , 2007 .
[35] G. Schwarzer,et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. , 2007, The Cochrane database of systematic reviews.
[36] G. Guyatt,et al. Systematic reviewers neglect bias that results from trials stopped early for benefit. , 2007, Journal of clinical epidemiology.
[37] R. Gascoyne,et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial , 2007 .
[38] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[39] T. Ittel,et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Stevens,et al. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. , 2007, Cancer treatment reviews.
[41] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] W. Hiddemann,et al. Clinical Trials and Observations , 2005 .
[43] J. Martínez-López,et al. Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03). , 2006 .
[44] P. Giraldo,et al. Maintenance Treatment with Rituximab in Follicular NHL. , 2006 .
[45] S. Leppä,et al. Cost-Effectiveness of Rituximab Maintenance Treatment Versus Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed Follicular Lymphoma (FL). , 2006 .
[46] A. Ho,et al. A Phase IIIb Study of Rituximab Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy - MAXIMA-Protocol. , 2006 .
[47] A. Krämer,et al. Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[49] J. Shortt,et al. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma , 2006, Bone Marrow Transplantation.
[50] Y. Ohashi,et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphoma , 2006, Cancer science.
[51] F. Barkhof,et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.
[52] G. Rossi,et al. Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments , 2006, Leukemia & lymphoma.
[53] J. Bohlius,et al. Fourth biannual report of the Cochrane Haematological Malignancies Group. , 2005, Journal of the National Cancer Institute.
[54] M. Ghielmini. Patient benefits of maintenance immunotherapy. , 2006, Leukemia research.
[55] P. Solal-Céligny. Safety of rituximab maintenance therapy in follicular lymphomas. , 2006, Leukemia research.
[56] W. Hiddemann. Rituximab maintenance therapy in follicular lymphoma comes of age. , 2006, Leukemia research.
[57] M. Ghielmini. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma. , 2005, Cancer treatment reviews.
[58] R. Gascoyne,et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. , 2005 .
[59] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[60] E. Cesarman,et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. , 2005, Blood.
[61] C. Lynch,et al. Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] A. Krämer,et al. Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin’s-lymphoma: First interim results of a prospective randomised phase II study , 2005 .
[63] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] N. Mendenhall,et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[66] R. Fisher. Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. , 2005, Clinical advances in hematology & oncology : H&O.
[67] S. H. Lim,et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia , 2005, Bone Marrow Transplantation.
[68] S. Cadrin,et al. A Preliminary Analysis , 2005 .
[69] Michael E. Williams. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma. , 2004, Current hematology reports.
[70] R. Gascoyne,et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[72] [Milestone in healing fatal indolent lymphoma]. , 2004, Krankenpflege Journal.
[73] Rituximab maintenance stretches progression-free survival in patients with indolent NHL. , 2004, Oncology.
[74] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[75] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[76] E. Lanino,et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. , 2003, Journal of hematotherapy & stem cell research.
[77] W. Hiddemann,et al. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. , 2003, Seminars in oncology.
[78] M. Herold,et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab , 2003, Annals of Hematology.
[79] A. Hagenbeek,et al. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial – Intergroup Collaborative Study , 2002, Annals of Hematology.
[80] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[81] J. Hainsworth. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. , 2002, Seminars in oncology.
[82] B. Coiffier. Rituximab in Combination with Chop Improves Survival in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma , 2002, Tumori.
[83] Rituxan delays disease progression in indolent non-Hodgkin's lymphoma. , 2002, Oncology.
[84] P. Mclaughlin,et al. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. , 2002, Seminars in oncology.
[85] P. Mclaughlin,et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. , 2000, Seminars in oncology.
[86] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[88] R. Holman,et al. Progressive Multifocal Leukoencephalopathy in the United States, 1979–1994: Increased Mortality Associated with HIV Infection , 1998, Neuroepidemiology.
[89] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. McDonnell,et al. The neurologic complications of B-cell chronic lymphocytic leukemia , 1997, Neurology.
[91] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[92] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[93] C. Haanen,et al. Major complications and causes of death in patients treated for Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[95] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[96] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.